UK-based life sciences company Cypralis has secured funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop new cyclophilin inhibitors for neurodegenerative diseases.
The $524,000 funding will help augment the existing collaboration, which is facilitated by Johnson & Johnson Innovation, between Cypralis and Janssen Pharmaceuticals to develop the inhibitors.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cypralis CSO Dr Michael Peel said: "The ADDF funding opens an exciting pathway towards developing a novel class of cyclophilin D inhibitors for neurodegenerative diseases, including Alzheimer’s.
“Many previous publications have recognised the potential for cyclophilin D as a novel target for degenerative disease but no group has published on compounds that combine sub-type selectivity and brain penetration.
“If data from the ADDF funding is encouraging, Cypralis would expect to initiate a lead optimisation campaign in early 2018 with the goal of generating a novel pre-clinical candidate for this extremely challenging and devastating disease."
Cyclophilin inhibitors are non-selective between the four commonly screened cyclophilin isoforms known as A, B, C and D.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAt present, a joint research programme is being carried out by Cypralis and Janssen to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D to target degenerative diseases, including CNS degeneration.
With the ADDF funding, Cypralis will be able to extend ‘hit-to-lead’ medicinal chemistry and expand its brain-penetrant cyclophilin inhibitors.
In 2013, Cypralis was spun out from Selcia to exploit its expertise in targeting peptidyl-prolyl isomerases involved in many acute and chronic diseases.
